Proof - skvi10q.htm

0001663577-21-000297.txt : 20210615 0001663577-21-000297.hdr.sgml : 20210615 20210615162623 ACCESSION NUMBER: 0001663577-21-000297 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210615 DATE AS OF CHANGE: 20210615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SKINVISIBLE, INC. CENTRAL INDEX KEY: 0001085277 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880344219 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-25911 FILM NUMBER: 211018829 BUSINESS ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: SUITE 10 CITY: LAS VEGAS STATE: NV ZIP: 89120 BUSINESS PHONE: 7024337154 MAIL ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: SUITE 10 CITY: LAS VEGAS STATE: NV ZIP: 89120 FORMER COMPANY: FORMER CONFORMED NAME: SKINVISIBLE INC DATE OF NAME CHANGE: 19990428 10-Q 1 skvi10q.htm Proof - skvi10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended March 31, 2021

[ ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from __________ to __________

	Commission File Number: 000-25911

Skinvisible, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	88-0344219
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

6320 South Sandhill Road, Suite 10, Las Vegas, NV 89120

(Address of principal executive offices)

702.433.7154

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

[ ] Large accelerated filer	[ ] Accelerated filer
[X] Non-accelerated filer	[X] Smaller reporting company
	[ ] Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 4,539,843 common shares as of June 9, 2021

Table of Contents

	TABLE OF CONTENTS	Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	6
Item 4:	Controls and Procedures	7
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	8
Item 1A:	Risk Factors	8
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	8
Item 3:	Defaults Upon Senior Securities	8
Item 4:	Mine Safety Disclosure	8
Item 5:	Other Information	8
Item 6:	Exhibits	8

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

F-1

Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 (unaudited);

F-2

Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and March 31, 2020 (unaudited);

F-3

Condensed Consolidated Statements of Stockholders’ Deficit for the three months ended March 31, 2021 and 2020 (unaudited);

F-4

Condensed Consolidated Statements of Cash Flow for the three months ended March 31, 2021 and 2020 (unaudited);

F-5

Notes to Condensed Consolidated Financial Statements.

Table of Contents

SKINVISIBLE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	March 31, 2021			December 31, 2020
ASSETS
Current assets
Cash	$	12,667		$	35,896
Accounts receivable		6,500			7,718
Prepaid expense and other current assets		3,250			6,500
Total current assets		22,417			50,114

Patents and trademarks, net		146,329			150,130

Total assets	$	168,746		$	200,244

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued liabilities	$	952,243		$	865,497
Accounts payable related party		500			7,616
Accrued interest payable		1,140,282			1,021,373
Derivative liability		40,471			—
Loans from related party		52,499			52,499
Notes payable		552,000			552,000
Convertible notes payable		220,000			220,000
Total current liabilities		2,957,995			2,718,985

Convertible notes payable related party, net of unamortized discount of $2,447,770 and $3,060,970 respectively		1,939,902			1,787,439
Convertible notes payable, net of unamortized debt discount of $203,476 and $54,450, respectively, less current portion		161,133			148,599

Total liabilities		5,059,030			4,655,023

Stockholders' deficit
Common stock; $0.001 par value; 200,000,000 shares authorized; 4,539,843 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		4,540			4,540
Shares payable		—			—
Additional paid-in capital		30,241,089			30,241,089
Accumulated deficit		(35,135,913	)		(34,700,408)
Total stockholders' deficit		(4,890,284	)		(4,454,779)

Total liabilities and stockholders' deficit	$	168,746		$	200,244

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-1

Table of Contents

SKINVISIBLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three months ended
	March 31, 2021			March 31, 2020

Revenues	$	12,051		$	16,052

Cost of revenues		3,300			—

Gross profit		8,751			16,052

Operating expenses
Depreciation and amortization		4,251			9,720
Selling general and administrative		115,627			136,324
Total operating expenses		119,878			146,044

Loss from operations		(111,127	)		(129,992)

Other expense
Interest expense		(283,907	)		(300,092)
Loss on change of derivative liability		(40,471	)
Total other expense		(324,378	)		(300,092)

Net loss		(435,505	)	$	(430,084)

Basic loss per common share		(0.10	)	$	(0.10)

Fully diluted loss per common share		(0.10	)	$	(0.10)


Basic weighted average common shares outstanding		4,539,843			4,471,746


Fully diluted weighted average common shares outstanding		4,539,843			4,471,746

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-2

Table of Contents

SKINVISIBLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(Unaudited)

	Common Stock
	Shares		Amount		Additional Paid-in Capital		Shares payable		Accumulated Deficit			Total Stockholders’ Deficit
Balance, December 31, 2020	4,539,843	$	4,540	$	30,241,089	$	—	$	(34,700,408	)	$	(4,454,779)
Net loss	—		—		—		—		(435,505	)		(435,505)
Balance, March 31, 2021	4,539,843	$	4,540	$	30,241,089	$	—	$	(35,135,193	)	$	(4,890,284)

Balance, December 31, 2019	4,471,746	$	4,472	$	30,181,555	$	59,602	$	(33,252,796	)	$	(3,007,167)
Net loss	—		—		—		—		(430,084	)		(430,084)
Balance, March 31, 2020	4,471,746	$	4,472	$	30,181,555	$	59,602	$	(33,682,880	)	$	(3,437,251)

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-3

Table of Contents

SKINVISIBLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three months ended
	March 31, 2021			March 31, 2020

Cash flows from operating activities:
Net loss	$	(435,505	)	$	(430,084)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		4,251			9,720
Amortization of debt discount		164,997			165,137
Loss on change of derivative liability		40,471			—
Changes in operating assets and liabilities:
Decrease (Increase) in prepaid assets		3,250			1,625
Decrease (Increase) in accounts receivable		1,218			1,795
Increase in accounts payable and accrued liabilities		86,746			101,003
Decrease in due from related party		—
Increase in accrued interest		118,909			134,955
Net cash provided used in operating activities		(15,663	)		(15,849)

Cash flows from investing activities:
Purchase of fixed and intangible assets		(450	)		(870)
Net cash used in investing activities		(450	)		(870)

Cash flows from financing activities:
Payments on related party loans		(7,116	)		—
Proceeds from related party loans		—			22,000
Net cash provided by (used in) financing activities		(7,116	)		22,000

Net change in cash		(23,229	)		5,281

Cash, beginning of period		35,896			1,298

Cash, end of period	$	12,667		$	6,579

Supplemental disclosure of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for tax	$	—		$	—

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Non-cash investing and financing activities:

See Accompanying Notes to Consolidated Financial Statements.

F-4

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History – The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

2. BASIS OF PRESENTATION AND GOING CONCERN

Basis of presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X , and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements on Form 10-K filed with the SEC on April 15, 2021. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the three months ended March 31, 2021, the Company had a net loss of $435,505 The Company has also incurred cumulative net losses of $35,135,913 since its inception and requires capital for its contemplated operational and marketing activities to take place. These factors, among others, raises substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing.

Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding. However, the Company’s ability to generate the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

COVID-19 Pandemic

In December 2019, an outbreak of a novel strain of coronavirus originated in Wuhan, China (“COVID-19”) and has since spread worldwide, including to the Unites States, posing public health risks that have reached pandemic proportions (the “COVID-19 Pandemic”). The COVID-19 Pandemic poses a threat to the health and economic wellbeing of our employees, customers and vendors. Like most businesses world-wide, the COVID-19 Pandemic has impacted the Company financially; however, management cannot presently predict the scope and severity with which COVID-19 will impact our business, financial condition, results of operations and cash flows.

3. SUMMARY OF SIGNIFICANT POLICIES

This summary of significant accounting policies of Skinvisible Inc. is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements.

F-5

Table of Contents

Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions have been eliminated.

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s, impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Cash and cash equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents.

Accounting for Derivatives - The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a Binomial lattice pricing model to value the derivative instruments at inception and on subsequent valuation dates.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Fair Value of financial instruments –The carrying value of cash, accounts payable and accrued expenses, and debt approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s convertible debt is also stated at a fair value since the stated rate of interest approximates market rates.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.

•

Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features.

•

Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.

•

Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.

Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2021:

	Level 1		Level 2		Level 3		Total
Liabilities
Derivative Financial Instruments	$	—	$	—	$	40,471	$	40,471

As of March 31, 2021, the Company’s used the following assumptions to value the derivative liabilities using the for Binomial-Lattice valuation model. Stock price was $0.11, term 0.50 years, risk-free discount rate of 0.16% and volatility of 110.66%

F-6

Table of Contents

The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs:

	Amount
Balance December 31, 2020	$	—
Change in fair market value of derivative liabilities		40,471
Balance March 31, 2021	$	40,471

Revenue recognition – We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise taxes).

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of March 31, 2021 and December 31, 2020, the Company had not recorded a reserve for doubtful accounts.

Stock-based compensation - The Company records stock based compensation in accordance with the guidance in ASC Topic 505 and 718 which requires the Company to recognize expenses related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award.

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with ASC 718-10 and the conclusions reached by the ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 505-50.

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented for the quarter ending March 31, 2021, since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 30,779,400 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of March 31, 2021. The shares issuable under each instrument is as follows; 100,000 shares issuable for options, 60,000 shares issuable for warrants, and 30,619,400 shares issuable under convertible notes.

Recently issued accounting pronouncements – The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.

F-7

Table of Contents

4. INTANGIBLE AND OTHER ASSETS

Patents and trademarks and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. As of March 31, 2021, intangible assets total $261,726, net of $115,846 of accumulated amortization. As of December 31, 2020, intangible assets total $261,726, net of $111,596 of accumulated amortization.

Amortization expense for the three months ended March 31, 2021 and 2020 was $4,251 and $9,720, respectively. License and distributor rights were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of March 31, 2021.

5. RELATED PARTY TRANSACTIONS

During the three months ended March 31, 2021 and 2020, $0 and $22,000 was advanced by an officer and $7,616 and $0 was repaid, respectively .

As of March 31, 2021 and December 31, 2020, $52,499 and $52,499 in advances remained due to officers of the company, respectively. All other related party notes have been extinguished or re-negotiated as convertible notes.

Convertible Notes Related Party

Convertible Notes Payable Related Party consists of the following:	March 31, 2021			December 31, 2020
On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been accreted and charged to interest expenses as a financing expense in the amount of $105,880 during the year ended March 31, 2021 and 2020, respectively.	$	4,235,209		$	4,235,209
Unamortized debt discount		(2,295,307	)		(2,447,770)
Total, net of unamortized discount	$	1,939,302		$	1,787,439

6. NOTES PAYABLE

Secured debt offering

During the period from May 22, 2013 and December 31, 2018, the Company entered into a 9% notes payable to nineteen investors and received proceeds of $552,000. The notes were due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.”

As of March 31, 2021, $552,000 of the outstanding notes payable are past due and in default and have been classified as current notes payable.

F-8

Table of Contents

7. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable consists of the following:	March 31,			December 31,
	2021			2020
$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $7,358. The Company determined the derivative was immaterial as of December 31, 2020. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		40,000			40,000
Original issue discount		—			—
Unamortized debt discount		—			—
Total, net of unamortized discount		40,000			40,000

On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $24,834. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		135,000			135,000
Unamortized debt discount		—			—
Total, net of unamortized discount		135,000			135,000

On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $3,679. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		20,000			20,000
Unamortized debt discount		—			—
Total, net of unamortized discount		20,000			20,000

On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $2,759. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		15,000			15,000
Unamortized debt discount		—			—
Total, net of unamortized discount		15,000			15,000

On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $1,840. The Company determined the derivative was immaterial as of December 31, 2020 The note has reached maturity and is in default.		10,000			10,000
Unamortized debt discount		—			—
Total, net of unamortized discount		10,000			10,000

On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses in the amount of $12,534 and $12,674 for the three months ended March 31, 2021 and 2020, respectively.		352,075			352,075
Unamortized debt discount		(190,942	)		(203,476
Total, net of unamortized discount		161,133			148,599

Total Convertible Notes	$	381,133	$	368,599
Current portion:		220,000		220,000
Total long-term convertible notes	$	161,133	$	148,599

The Company determined the derivative liability of the options using the Binomial model. The variables used for the Binomial model as of March 31, 2021 are as listed below:

Risk free interest rate	0.16	%
Expected term (years)	.50
Expected volatility	110.66	%

F-9

Table of Contents

8. COMMITMENTS AND CONTINGENCIES

License Agreement

On October 17, 2019, Skinvisible entered an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to Skinvisible a license fee of $1,000,000 and a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to Skinvisible upon achieving regulatory approval milestones for certain drug products.

The agreement is subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated on December 31, 2019. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement, as amended under the same terms to expire on September 30, 2020 and on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely. The milestones have not been reached as of March 31, 2021. The initial licensing fee has not been accrued due to the uncertainty of its collection.

On February 3, 2020, we entered into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the agreement was further amended to provide additional assignment rights for its hand sanitizer products in exchange for $100,000.

9. STOCK OPTIONS AND WARRANTS

The following is a summary of option activity during the three months ended March 31, 2021.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2020		100,000		1. 51

Options granted and assumed		—		—
Options expired		—		—
Options canceled		—		—
Options exercised		—		—

Balance, March 31, 2021		100,000		1. 51

As of March 31, 2021, all stock options outstanding are exercisable.

Stock warrants -

The following is a summary of warrants activity during the year ended March 31, 2021.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2020		60,000	$	1.18

Warrants granted and assumed		—		—
Warrants expired		—		—
Warrants canceled		—		—
Warrants exercised		—		—

Balance, March 31, 2021		60,000	$	1.18

As of March 31, 2021, all stock warrants outstanding are exercisable.

10. STOCKHOLDERS’ DEFICIT

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 4,539,843 and 4,539,843 issued and outstanding shares of common stock as of March 31, 2021 and December 31, 2020, respectively.

11. SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to March 31, 2021 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

F-10

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Overview

COVID-19

The full extent of the impact of the COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict at the present time. In an effort to contain COVID-19 or slow its spread, governments around the world have enacted various measures, including orders to close all businesses not deemed “essential,” isolate residents to their homes or places of residence, and practice social distancing when engaging in essential activities. We anticipate that these actions and the global health crisis caused by COVID-19 will negatively impact business activity across the globe. While we have not observed any noticeable impact on our revenue related to these conditions in the past fiscal year, or through the date of this filing, we cannot estimate the impact COVID-19 will have in the future as business and consumer activity decelerates across the globe.

We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state, local or foreign authorities, or that we determine are in the best interests of our employees, customers, partners and stockholders. It is not clear what the potential effects any such alterations or modifications may have on our business, including the effects on our customers, partners, or vendors, or on our financial results.

Recent Developments

On October 17, 2019, we entered an Exclusive License Agreement with Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin”) pursuant to which we granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to us a license fee of $1,000,000 (the “License Fee”) and a single digit royalty interest of all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to us upon achieving regulatory approval milestones for certain drug products.

The agreement was subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement under the same terms to expire on September 30, 2020, and on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely. As of March 31, 2021, we have received $125,000 in licensing fee income per this agreement.

On February 3, 2020, we entered into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee of $100,000 payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the company exercised its rights and paid the $100,000 license fee.

Table of Contents

Results of Operations for the Three Months Ended March 31, 2021 and 2020

Revenues

Our revenue, which we combine from product sales, royalties on patent licenses and license fees (product development fees), was $12,051 for the three months ended March 31, 2021, a decrease from $16,052 for the same period ended March 31, 2020.

The revenue for both periods was mainly from license fees, but we did have some product sales in the 2021 quarter. We hope to generate more revenues from our licenses with Quoin and Ovation for the rest of the year.

Gross Profit

We had $3,300 in cost of revenues for the three months ended March 31, 2021, as compared with no cost of revenues for the same period ended 2020, so our gross profit was $8,751 for the three months ended March 31, 2021, as compared with gross profit of $16,052 for the three months ended March 31, 2020.

We had some product sales resulting in a reduced gross profit for 2021 as compared with 2020. We hope that our gross profit increases in 2021 with more revenues from our licenses with Quoin and Ovation expected for the rest of the year, which do not have a cost of revenue component.

Operating Expenses

Operating expenses decreased to $119,878 for the three months ended March 31, 2021 from $146,044 for the same period ended March 31, 2020.

Our operating expenses for the three months ended March 31, 2021 consisted mainly of accrued salaries and wages of $87,942, audit and accounting of $13,610, and amortization of $4,251. In comparison, our operating expenses for the three months ended March 31, 2020 consisted mainly of accrued salaries and wages of $87,942, audit and accounting of $28,870, and amortization of $9,719.

Other Expenses

We had other expenses of $324,378 for the three months ended March 31, 2021, as compared with other expenses of $300,092 for the three months ended March 31, 2020. The increase in other expenses was primarily a result of a loss on change od derivative liability in the amount of $40,471.

We expect to experience high debt payments in the future as a result of our outstanding liabilities. Moreover, as of the date of this report, there are a number of secured promissory notes with an aggregate principal amount of approximately $772,000 that have matured. In addition, we also have one unsecured promissory note with an aggregate principal amount of $10,000 that has matured. If we are unable to generate sufficient revenues and/or additional financing to service this debt, there is a risk the lenders will call the notes, secure our assets, as to those applicable secured notes, and demand payment. If this happens, we could go out of business.

Net Loss

We recorded a net loss of $435,505 for the three months ended March 31, 2021, as compared with a net loss of $430,084 for the three months ended March 31, 2020.

Liquidity and Capital Resources

As of March 31, 2021, we had total current assets of $22,417 and total assets in the amount of $168,746. Our total current liabilities as of March 31, 2021 were $2,957,995. We had a working capital deficit of $2,935,578 as of March 31, 2021, compared with a working capital deficit of $2,668,871 as of December 31, 2020.

Operating activities used $16,116 in cash for the three months ended March 31, 2021, as compared with $15,849 used for the three months ended March 31, 2020. Our negative operating cash flow for each period was largely the result of our net losses for those periods, offset by adjustments to amortization of debt discount and increases in accrued interest.

We used cash of $0 and $870 in investing activities for the three months ended March 31, 2021 and 2020, respectively, for the purchase of fixed and intangible assets.

Cash flows used by financing activities during the three months ended March 31, 2021 amounted to $7,616, as compared with cash provided of $22,000 for the three months ended March 31, 2021. Our cash flow for the three months ended March 31, 2021 consisted of repayments of related party loans. Our cash flow for the three months ended March 31, 2020 consisted of proceeds from related party loans.

The features of the debt instruments and payables concerning our financing activities are detailed in the footnotes to our financial statements.

Table of Contents

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred cumulative net losses of $35,135,913 since our inception and require capital for our contemplated operational and marketing activities to take place. Our ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of our contemplated plan of operations, and our transition, ultimately, to the attainment of profitable operations are necessary for us to continue operations. The ability to successfully resolve these factors raise substantial doubt about our ability to continue as a going concern. These consolidated financial statements do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Off Balance Sheet Arrangements

As of March 31, 2021, there were no off balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Distribution and license rights sales – We also recognize revenue from distribution and license rights only when earned (and are amortized over a five-year period), with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of March 31, 2021, we had not recorded a reserve for doubtful accounts. We have $175,000in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Recently Issued Accounting Pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Table of Contents

Item 4.

Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2021. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2021, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of March 31, 2021, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending December 31, 2021: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the nine months ended March 31, 2021 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A.

Risk Factors

See risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed on April 15, 2021.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults upon Senior Securities

None

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None

Item 6.

Exhibits

Exhibit Number Description of Exhibit

31.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101**

The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 formatted in Extensible Business Reporting Language (XBRL).

**Provided herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Skinvisible, Inc.

Date: June 15, 2021

By: /s/ Terry Howlett

Terry Howlett

Title: Chief Executive Officer, Chief Financial Officer and Director

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-31.1 3 ex31_1.htm

CERTIFICATIONS

I, Terry Howlett, certify that;

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 of Skinvisible, Inc. (the “registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 15, 2021

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Executive Officer

EX-31.2 4 ex31_2.htm

CERTIFICATIONS

I, Terry Howlett, certify that;

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 of Skinvisible, Inc. (the “registrant”);

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 15, 2021

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Financial Officer

EX-32.1 5 ex32_1.htm

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Skinvisible, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2021 filed with the Securities and Exchange Commission (the “Report”), I, Terry Howlett, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Terry Howlett
Name:	Terry Howlett
Title:	Principal Executive Officer, Principal Financial Officer and Director
Date:	June 15, 2021

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EX-101.INS 6 skvi-20210331.xml XBRL INSTANCE FILE 0001085277 2021-01-01 2021-03-31 0001085277 2021-03-31 0001085277 2020-12-31 0001085277 2020-01-01 2020-03-31 0001085277 2019-12-31 0001085277 2020-03-31 0001085277 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001085277 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001085277 us-gaap:CommonStockMember 2020-12-31 0001085277 us-gaap:CommonStockMember 2021-03-31 0001085277 us-gaap:CommonStockMember 2019-12-31 0001085277 us-gaap:CommonStockMember 2020-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001085277 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001085277 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001085277 us-gaap:TreasuryStockMember 2020-12-31 0001085277 us-gaap:TreasuryStockMember 2021-03-31 0001085277 us-gaap:TreasuryStockMember 2019-12-31 0001085277 us-gaap:TreasuryStockMember 2020-03-31 0001085277 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001085277 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001085277 us-gaap:RetainedEarningsMember 2020-12-31 0001085277 us-gaap:RetainedEarningsMember 2021-03-31 0001085277 us-gaap:RetainedEarningsMember 2019-12-31 0001085277 us-gaap:RetainedEarningsMember 2020-03-31 0001085277 1998-09-06 2021-03-31 0001085277 SKVI:OptionsMember 2021-01-01 2021-03-31 0001085277 SKVI:WarrantsMember 2021-01-01 2021-03-31 0001085277 SKVI:ConvertibleNotesMember 2021-01-01 2021-03-31 0001085277 SKVI:RelatedPartyNotesPayableOneMember 2021-03-31 0001085277 SKVI:RelatedPartyNotesPayableOneMember 2019-12-31 0001085277 2019-06-30 0001085277 2019-01-01 2019-06-30 0001085277 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-03-31 0001085277 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-03-31 0001085277 SKVI:NineteenNotesPayableMember 2013-05-22 2018-12-31 0001085277 SKVI:NineteenNotesPayableMember 2018-12-31 0001085277 SKVI:ConvertibleNote1Member 2021-03-31 0001085277 SKVI:ConvertibleNote2Member 2021-03-31 0001085277 SKVI:ConvertibleNote3Member 2021-03-31 0001085277 SKVI:ConvertibleNote4Member 2021-03-31 0001085277 SKVI:ConvertibleNote5Member 2021-03-31 0001085277 SKVI:ConvertibleNote6Member 2021-03-31 0001085277 SKVI:TotalConvertibleNotesMember 2021-03-31 0001085277 SKVI:ConvertibleNote1Member 2019-12-31 0001085277 SKVI:ConvertibleNote2Member 2019-12-31 0001085277 SKVI:ConvertibleNote3Member 2020-12-31 0001085277 SKVI:ConvertibleNote4Member 2019-12-31 0001085277 SKVI:ConvertibleNote5Member 2019-12-31 0001085277 SKVI:ConvertibleNote6Member 2019-12-31 0001085277 SKVI:TotalConvertibleNotesMember 2019-12-31 0001085277 SKVI:ConvertibleNote2Member 2021-01-01 2021-03-31 0001085277 SKVI:ConvertibleNote3Member 2021-01-01 2021-03-31 0001085277 SKVI:ConvertibleNote4Member 2021-01-01 2021-03-31 0001085277 SKVI:ConvertibleNote5Member 2021-01-01 2021-03-31 0001085277 SKVI:ConvertibleNote6Member 2021-01-01 2021-03-31 0001085277 SKVI:ConvertibleNote6Member 2020-01-01 2020-03-31 0001085277 SKVI:ConvertibleNoteOneMember 2021-03-31 0001085277 SKVI:ConvertibleNoteTwoMember 2015-10-26 0001085277 SKVI:ConvertibleNote3Member 2016-02-17 0001085277 SKVI:ConvertibleNoteFourMember 2016-08-11 0001085277 SKVI:ConvertibleNoteFiveMember 2017-01-27 0001085277 SKVI:ConvertibleNoteSixMember 2020-12-31 0001085277 2019-10-01 2019-10-17 0001085277 2020-06-01 2020-06-10 0001085277 SKVI:Level1Member 2021-03-31 0001085277 SKVI:Level2Member 2021-03-31 0001085277 SKVI:Level3Member 2021-03-31 0001085277 2021-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 10-Q false 2021-03-31 Q1 2021 --12-31 SKINVISIBLE, INC. 0001085277 Yes Non-accelerated Filer true false false

12667

35896

6579

6500

7718

3250

6500

22417

50114

168746

200244

952243

865497

500

7616

1140282

1021373

52499

552000

2957995

2718985

1939902

1787439

161133

148599

4235209

40000

135000

20000

15000

10000

352075

381133

40000

135000

20000

15000

10000

352075

368599

5059030

4655023

30241089

-35135913

-34700408

-4890284

-4454779

168746

200244

146329

150130

220000

4540

12051

16052

3300

8751

16052

4251

9720

115627

136324

119878

146044

-111127

-129992

283907

300092

324378

300092

-0.10

4539843

4471746

4539843

4471746

-435505

-430084

-435505

-430084

-35135913

164997

165137

3250

1625

1218

1795

86746

101003

118909

134955

966203

119278

450

870

7116

22000

-23229

5281

35896 1298

3369244

280076

-15663

-15849

-450

-870

-7116

22000

4539843

4471746

44714746

-4890284

-4454779

-3007167

-3437251

4540

4472

30241089

30181555

56602

59602

-34700408

-35135193

-33252796

-33682880

1998-03-06

30779400

100000

60000

30619400

261726

111596

4251

9720

2295307

2447770

40000

135000

20000

15000

10000

161133

40000

135000

20000

15000

10000

148599

203476

54450

1939302

1787439

2464480

40000

135000

20000

15000

10000

The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.

617915

7260

64423

1473

11942

110245

105590

50974

25626

52499

22000

0.09

0.10

552000

P2Y

190942

203476

220000

2017-10-26

2018-02-17

2018-08-11

2019-01-27

224064

0.90

100000

1.51

60000

1.18

0.001

200000000

4539843

40471

-40471

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 41%">Liabilities</td><td style="width: 3%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 3%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 3%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 3%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Derivative Financial Instruments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,471</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,471</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5pt; width: 71%">Balance December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 18%">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">Change in fair market value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,471</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5pt">Balance March 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,471</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Convertible Notes Payable Related Party consists of the following:</td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">March 31, 2021</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; width: 73%">On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.   The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been accreted and charged to interest expenses as a financing expense in the amount of $105,880 during the year ended March 31, 2021 and 2020, respectively. </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 1%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 11%">4,235,209</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 1%">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 11%">4,235,209</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unamortized debt discount</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,295,307</td> <td>)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,447,770)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total, net of unamortized discount</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,939,302</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,787,439</td></tr> </table>

2447770 3060970

4539843

1000000

0.50

125000

100000

40471

0.11

<div style="font: 10pt Times New Roman, Times, Serif">1.       DESCRIPTION OF BUSINESS AND HISTORY   Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.   History – The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.    Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”</div>

<div style="font: 10pt Times New Roman, Times, Serif">2.       BASIS OF PRESENTATION AND GOING CONCERN   Basis of presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X , and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements on Form 10-K filed with the SEC on April 15, 2021. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.   The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.   Going concern –   The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the three months ended March 31, 2021, the Company had a net loss of $435,505 The Company has also incurred cumulative net losses of $35,135,913 since its inception and requires capital for its contemplated operational and marketing activities to take place. These factors, among others, raises substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing.   Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding. However, the Company’s ability to generate the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.   COVID-19 Pandemic   In December 2019, an outbreak of a novel strain of coronavirus originated in Wuhan, China (“COVID-19”) and has since spread worldwide, including to the Unites States, posing public health risks that have reached pandemic proportions (the “COVID-19 Pandemic”). The COVID-19 Pandemic poses a threat to the health and economic wellbeing of our employees, customers and vendors. Like most businesses world-wide, the COVID-19 Pandemic has impacted the Company financially; however, management cannot presently predict the scope and severity with which COVID-19 will impact our business, financial condition, results of operations and cash flows.</div>

<div style="font: 10pt Times New Roman, Times, Serif">3.       SUMMARY OF SIGNIFICANT POLICIES   This summary of significant accounting policies of Skinvisible Inc. is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements.       Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions have been eliminated.   Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s, impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.   Cash and cash equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents.   Accounting for Derivatives - The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a Binomial lattice pricing model to value the derivative instruments at inception and on subsequent valuation dates.   The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.   Fair Value of financial instruments –The carrying value of cash, accounts payable and accrued expenses, and debt approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s convertible debt is also stated at a fair value since the stated rate of interest approximates market rates.   Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 16px"> </td> <td style="font: 11pt/90% Calibri, Helvetica, Sans-Serif; width: 13px; text-align: justify">•</td> <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify">Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features. </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.</td></tr> </table>   Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2021:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: left">Derivative Financial Instruments</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">40,471</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">40,471</td></tr> </table>   As of March 31, 2021, the Company’s used the following assumptions to value the derivative liabilities using the for Binomial-Lattice valuation model. Stock price was $0.11, term 0.50 years, risk-free discount rate of 0.16% and volatility of 110.66%   The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5pt">Balance December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">Change in fair market value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">40,471</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5pt">Balance March 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,471</td></tr> </table>   Revenue recognition – We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.   Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.   Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.   Distribution and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.   The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise taxes).   Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of March 31, 2021 and December 31, 2020, the Company had not recorded a reserve for doubtful accounts.   Stock-based compensation - The Company records stock based compensation in accordance with the guidance in ASC Topic 505 and 718 which requires the Company to recognize expenses related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award.   The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with ASC 718-10 and the conclusions reached by the ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 505-50.    Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented for the quarter ending March 31, 2021, since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 30,779,400 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of March 31, 2021. The shares issuable under each instrument is as follows; 100,000 shares issuable for options, 60,000 shares issuable for warrants, and 30,619,400 shares issuable under convertible notes.    Recently issued accounting pronouncements – The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.</div>

<div style="font: 10pt Times New Roman, Times, Serif">4.       INTANGIBLE AND OTHER ASSETS   Patents and trademarks and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. As of March 31, 2021, intangible assets total $261,726, net of $115,846 of accumulated amortization. As of December 31, 2020, intangible assets total $261,726, net of $111,596 of accumulated amortization.   Amortization expense for the three months ended March 31, 2021 and 2020 was $4,251 and $9,720, respectively. License and distributor rights were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of March 31, 2021.</div>

<div style="font: 10pt Times New Roman, Times, Serif">5.        RELATED PARTY TRANSACTIONS   During the three months ended March 31, 2021 and 2020, $0 and $22,000 was advanced by an officer and $7,616 and $0 was repaid, respectively .   As of March 31, 2021 and December 31, 2020, $52,499 and $52,499 in advances remained due to officers of the company, respectively. All other related party notes have been extinguished or re-negotiated as convertible notes.   Convertible Notes Related Party   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Convertible Notes Payable Related Party consists of the following:</td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">March 31, 2021</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td style="width: 73%; text-align: justify">On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.   The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been accreted and charged to interest expenses as a financing expense in the amount of $105,880 during the year ended March 31, 2021 and 2020, respectively. </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 1%">$</td> <td style="border-bottom: black 1pt solid; width: 11%; text-align: right">4,235,209</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 1%">$</td> <td style="border-bottom: black 1pt solid; width: 11%; text-align: right">4,235,209</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unamortized debt discount</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,295,307</td> <td>)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,447,770)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total, net of unamortized discount</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,939,302</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,787,439</td></tr> </table>  </div>

<div style="font: 10pt Times New Roman, Times, Serif">6.       NOTES PAYABLE   Secured debt offering During the period from May 22, 2013 and December 31, 2018, the Company entered into a 9% notes payable to nineteen investors and received proceeds of $552,000. The notes were due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.”   As of March 31, 2021, $552,000 of the outstanding notes payable are past due and in default and have been classified as current notes payable.</div>

<div style="font: 10pt Times New Roman, Times, Serif">7.       CONVERTIBLE NOTES PAYABLE   <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Notes Payable consists of the following:</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify; padding-bottom: 1pt">$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $7,358. The Company determined the derivative was immaterial as of December 31, 2020. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Original issue discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $24,834. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $3,679. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $2,759. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $1,840. The Company determined the derivative was immaterial as of December 31, 2020  The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.   The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses in the amount of $12,534 and $12,674 for the three months  ended March 31, 2021 and 2020, respectively.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,075</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,075</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(190,942</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(203,476</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">161,133</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">148,599</td></tr> </table> <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 69%"> Total Convertible Notes</td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 12%; text-align: right">381,133</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 12%; text-align: right">368,599</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Current portion:</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">220,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">220,000</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total long-term convertible notes</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">161,133</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">148,599</td></tr> </table>   The Company determined the derivative liability of the options using the Binomial model. The variables used for the Binomial model as of March 31, 2021 are as listed below:    <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 0.75pt">Risk free interest rate</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">0.16</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.75pt">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.75pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.66</td><td style="text-align: left">%</td></tr></table></div>

0.16

P6M

110.66

<div style="font: 10pt Times New Roman, Times, Serif">8.       COMMITMENTS AND CONTINGENCIES   License Agreement   On October 17, 2019, Skinvisible entered an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to Skinvisible a license fee of $1,000,000 and a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to Skinvisible upon achieving regulatory approval milestones for certain drug products.   The agreement is subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated on December 31, 2019. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement, as amended under the same terms to expire on September 30, 2020   and on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely. The milestones have not been reached as of March 31, 2021. The initial licensing fee has not been accrued due to the uncertainty of its collection.   On February 3, 2020, we entered into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the agreement was further amended to provide additional assignment rights for its hand sanitizer products in exchange for $100,000. </div>

<div style="font: 10pt Times New Roman, Times, Serif">9.       STOCK OPTIONS AND WARRANTS   The following is a summary of option activity during the three months ended March 31, 2021.   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 69%; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2020</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">100,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1. 51</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options granted and assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Options exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">100,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1. 51</td></tr> </table>   As of March 31, 2021, all stock options outstanding are exercisable.   Stock warrants -   The following is a summary of warrants activity during the year ended March 31, 2021.   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 69%; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2020</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">60,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">1.18</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrants granted and assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Warrants expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrants canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Warrants exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">60,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.18</td></tr> </table>   As of March 31, 2021, all stock warrants outstanding are exercisable.</div>

<div style="font: 10pt Times New Roman, Times, Serif">10.       STOCKHOLDERS’ DEFICIT   The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 4,539,843 and 4,539,843 issued and outstanding shares of common stock as of March 31, 2021 and December 31, 2020, respectively.</div>

<div style="font: 10pt Times New Roman, Times, Serif">11.       SUBSEQUENT EVENTS   In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to March 31, 2021 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.  </div>

<div style="font: 10pt Times New Roman, Times, Serif">Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions have been eliminated.</div>

<div style="font: 10pt Times New Roman, Times, Serif">Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s, impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</div>

<div style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents.</div>

<div style="font: 10pt Times New Roman, Times, Serif">Accounting for Derivatives - The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a Binomial lattice pricing model to value the derivative instruments at inception and on subsequent valuation dates.   The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.</div>

<div style="font: 10pt Times New Roman, Times, Serif">Fair Value of financial instruments –The carrying value of cash, accounts payable and accrued expenses, and debt approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s convertible debt is also stated at a fair value since the stated rate of interest approximates market rates.   Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 16px"> </td> <td style="font: 11pt/90% Calibri, Helvetica, Sans-Serif; width: 13px; text-align: justify">•</td> <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify">Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features. </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.</td></tr> </table>   Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2021:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: left">Derivative Financial Instruments</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">40,471</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">40,471</td></tr> </table>   As of March 31, 2021, the Company’s used the following assumptions to value the derivative liabilities using the for Binomial-Lattice valuation model. Stock price was $0.11, term 0.50 years, risk-free discount rate of 0.16% and volatility of 110.66%   The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5pt">Balance December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; text-align: left; padding-bottom: 1pt; padding-left: 0.5pt">Change in fair market value of derivative liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">40,471</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5pt">Balance March 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,471</td></tr></table></div>

<div style="font: 10pt Times New Roman, Times, Serif">Revenue recognition – We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.   Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.   Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.   Distribution and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.   The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise taxes).  </div>

<div style="font: 10pt Times New Roman, Times, Serif">Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of March 31, 2021 and December 31, 2020, the Company had not recorded a reserve for doubtful accounts.</div>

<div style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation - The Company records stock based compensation in accordance with the guidance in ASC Topic 505 and 718 which requires the Company to recognize expenses related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award.   The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with ASC 718-10 and the conclusions reached by the ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 505-50.</div>

<div style="font: 10pt Times New Roman, Times, Serif"> Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented for the quarter ending March 31, 2021, since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 30,779,400 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of March 31, 2021. The shares issuable under each instrument is as follows; 100,000 shares issuable for options, 60,000 shares issuable for warrants, and 30,619,400 shares issuable under convertible notes.</div>

<div style="font: 10pt Times New Roman, Times, Serif">Recently issued accounting pronouncements – The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.</div>

<table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Notes Payable consists of the following:</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify; padding-bottom: 1pt">$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $7,358. The Company determined the derivative was immaterial as of December 31, 2020. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">40,000</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Original issue discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $24,834. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $3,679. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $2,759. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $1,840. The Company determined the derivative was immaterial as of December 31, 2020  The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.   The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses in the amount of $12,534 and $12,674 for the three months  ended March 31, 2021 and 2020, respectively.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,075</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,075</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(190,942</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(203,476</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">161,133</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">148,599</td></tr> </table> <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 69%"> Total Convertible Notes</td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; width: 12%">381,133</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; width: 12%">368,599</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Current portion:</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">220,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">220,000</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total long-term convertible notes</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">161,133</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">148,599</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.75pt; width: 70%">Risk free interest rate</td><td style="width: 10%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 18%">0.16</td><td style="text-align: left; width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.75pt">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.75pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.66</td><td style="text-align: left">%</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; width: 69%">Balance, December 31, 2020</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; text-align: right; width: 12%">100,000</td><td style="padding-bottom: 1pt; text-align: left; width: 1%"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; text-align: right; width: 12%">1. 51</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options granted and assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Options exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">100,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1. 51</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; width: 69%">Balance, December 31, 2020</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; text-align: right; width: 12%">60,000</td><td style="padding-bottom: 1pt; text-align: left; width: 1%"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%">$</td><td style="border-bottom: Black 1pt solid; text-align: right; width: 12%">1.18</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrants granted and assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Warrants expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warrants canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Warrants exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">60,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.18</td></tr> </table>

Yes 4539843

EX-101.SCH 7 skvi-20210331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PERESENTATION AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - INTANGIBLE AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTIES POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Assets and Liabilities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Changes in Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - INTANGIBLE AND OTHER ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - RELATED PARTY TRANSACTIONS - Convertible Notes Payable Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - STOCKHOLDERS' DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 skvi-20210331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 skvi-20210331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 skvi-20210331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Additional Paid-In Capital Shares payable Accumulated Deficit Options Warrants Convertible Notes Debt Instrument [Axis] Related Party Notes Payable Related Party Transaction [Axis] Convertible Notes Payable Related Party Nineteen Notes Payable Convertible Note 1 Convertible Note 2 Convertible Note 3 Convertible Note 4 Convertible Note 5 Convertible Note 6 Total Convertible Notes Scenario [Axis] Convertible Note One Convertible Note Two Convertible Note Four Convertible Note Five Convertible Note Six Derivative Instrument [Axis] Level 1 Level 2 Level 3 Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash Accounts receivable Prepaid expense and other current assets Total current assets Patents and trademarks, net Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities Accounts payable related party Accrued interest payable Derivative liability Loans from related party Notes payable Convertible notes payable Total current liabilities Convertible notes payable related party, net of unamortized discount of $2,447,770 and $3,060,970 respectively Convertible notes payable, net of unamortized debt discount of $203,476 and $54,450, respectively, less current portion Total liabilities Stockholders' deficit Common stock; $0.001 par value; 200,000,000 shares authorized; 4,539,843 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively Shares payable Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Issued Common Stock, Outstanding Convertible Notes Payable, net of unamortized debt discount Convertible Notes Payable, related party, net of unamortized discount Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Depreciation and amortization Selling general and administrative Total operating expenses Loss from operations Other expense Interest expense Loss on change of derivative liability Total other expense Net loss Basic loss per common share Fully diluted loss per common share Basic weighted average common shares outstanding Fully diluted weighted average common shares outstanding Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, amount Net Income (loss) Ending balance, shares Ending balance, amount Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Amortization of debt discount Loss on change of derivative liability Changes in operating assets and liabilities: Decrease (Increase) in prepaid assets Decrease (Increase) in accounts receivable Increase in accounts payable and accrued liabilities Decrease in due from related party Increase in accrued interest Net cash provided used in operating activities Cash flows from investing activities: Purchase of fixed and intangible assets Net cash used in investing activities Cash flows from financing activities: Payments on related party loans Proceeds from related party loans Net cash provided by (used in) financing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for tax SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Non-cash investing and financing activities: Accounting Policies [Abstract] DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES BASIS OF PRESENTATION AND GOING CONCERN SUMMARY OF SIGNIFICANT POLICIES Notes to Financial Statements INTANGIBLE AND OTHER ASSETS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS NOTES PAYABLE CONVERTIBLE NOTES PAYABLE Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Temporary Equity Disclosure [Abstract] STOCK OPTIONS AND WARRANTS Equity [Abstract] STOCKHOLDERS DEFICIT Subsequent Events [Abstract] EX-101.PRE 11 skvi-20210331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2021	Jun. 09, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity Registrant Name	SKINVISIBLE, INC.
Entity Central Index Key	0001085277
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,539,843

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 12,667	$ 35,896
Accounts receivable	6,500	7,718
Prepaid expense and other current assets	3,250	6,500
Total current assets	22,417	50,114
Patents and trademarks, net	146,329	150,130
Total assets	168,746	200,244
Current liabilities
Accounts payable and accrued liabilities	952,243	865,497
Accounts payable related party	500	7,616
Accrued interest payable	1,140,282	1,021,373
Derivative liability	40,471
Loans from related party	52,499	52,499
Notes payable	552,000	552,000
Convertible notes payable	220,000	220,000
Total current liabilities	2,957,995	2,718,985
Convertible notes payable related party, net of unamortized discount of $2,447,770 and $3,060,970 respectively	1,939,902	1,787,439
Convertible notes payable, net of unamortized debt discount of $203,476 and $54,450, respectively, less current portion	161,133	148,599
Total liabilities	5,059,030	4,655,023
Stockholders' deficit
Common stock; $0.001 par value; 200,000,000 shares authorized; 4,539,843 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	4,540	4,540
Shares payable
Additional paid-in capital	30,241,089	30,241,089
Accumulated deficit	(35,135,913)	(34,700,408)
Total stockholders' deficit	(4,890,284)	(4,454,779)
Total liabilities and stockholders' deficit	$ 168,746	$ 200,244

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Issued	4,539,843	4,539,843
Common Stock, Outstanding	4,539,843	4,539,843
Convertible Notes Payable, net of unamortized debt discount	$ 203,476	$ 54,450
Convertible Notes Payable, related party, net of unamortized discount	$ 2,447,770	$ 3,060,970

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenues	$ 12,051	$ 16,052
Cost of revenues	3,300
Gross profit	8,751	16,052
Operating expenses
Depreciation and amortization	4,251	9,720
Selling general and administrative	115,627	136,324
Total operating expenses	119,878	146,044
Loss from operations	(111,127)	(129,992)
Other expense
Interest expense	(283,907)	(300,092)
Loss on change of derivative liability	(40,471)
Total other expense	(324,378)	(300,092)
Net loss	$ (435,505)	$ (430,084)
Basic loss per common share	$ (0.10)	$ (0.10)
Fully diluted loss per common share	$ (0.10)	$ (0.10)
Basic weighted average common shares outstanding	4,539,843	4,471,746
Fully diluted weighted average common shares outstanding	4,539,843	4,471,746

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Stockholders' Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Shares payable	Accumulated Deficit	Total
Beginning balance, shares at Dec. 31, 2019	4,471,746
Beginning balance, amount at Dec. 31, 2019	$ 4,472	$ 30,181,555	$ 56,602	$ (33,252,796)	$ (3,007,167)
Net Income (loss)				(430,084)	(430,084)
Ending balance, shares at Mar. 31, 2020	44,714,746
Ending balance, amount at Mar. 31, 2020	$ 4,472	30,181,555	59,602	(33,682,880)	$ (3,437,251)
Equity [Abstract]
STOCKHOLDERS DEFICIT					10. STOCKHOLDERS’ DEFICIT The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 4,539,843 and 4,539,843 issued and outstanding shares of common stock as of March 31, 2021 and December 31, 2020, respectively.
Beginning balance, shares at Dec. 31, 2020	4,539,843
Beginning balance, amount at Dec. 31, 2020	$ 4,540	30,241,089		(34,700,408)	$ (4,454,779)
Net Income (loss)				(435,505)	(435,505)
Ending balance, shares at Mar. 31, 2021	4,539,843
Ending balance, amount at Mar. 31, 2021	$ 4,540	$ 30,241,089		$ (35,135,193)	$ (4,890,284)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (435,505)	$ (430,084)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,251	9,720
Amortization of debt discount	164,997	165,137
Loss on change of derivative liability	40,471
Changes in operating assets and liabilities:
Decrease (Increase) in prepaid assets	3,250	1,625
Decrease (Increase) in accounts receivable	1,218	1,795
Increase in accounts payable and accrued liabilities	86,746	101,003
Decrease in due from related party
Increase in accrued interest	118,909	134,955
Net cash provided used in operating activities	(15,663)	(15,849)
Cash flows from investing activities:
Purchase of fixed and intangible assets	(450)	(870)
Net cash used in investing activities	(450)	(870)
Cash flows from financing activities:
Payments on related party loans	(7,116)
Proceeds from related party loans		22,000
Net cash provided by (used in) financing activities	(7,116)	22,000
Net change in cash	(23,229)	5,281
Cash, beginning of period	35,896	1,298
Cash, end of period	12,667	6,579
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for tax

XML 18 R7.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND HISTORY	3 Months Ended
DESCRIPTION OF BUSINESS AND HISTORY	Mar. 31, 2021
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES	1. DESCRIPTION OF BUSINESS AND HISTORY Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada. History – The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc. Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

XML 19 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PERESENTATION AND GOING CONCERN	3 Months Ended
BASIS OF PERESENTATION AND GOING CONCERN	Mar. 31, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND GOING CONCERN	2. BASIS OF PRESENTATION AND GOING CONCERN Basis of presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X , and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements on Form 10-K filed with the SEC on April 15, 2021. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements. Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the three months ended March 31, 2021, the Company had a net loss of $435,505 The Company has also incurred cumulative net losses of $35,135,913 since its inception and requires capital for its contemplated operational and marketing activities to take place. These factors, among others, raises substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing. Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding. However, the Company’s ability to generate the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties. COVID-19 Pandemic In December 2019, an outbreak of a novel strain of coronavirus originated in Wuhan, China (“COVID-19”) and has since spread worldwide, including to the Unites States, posing public health risks that have reached pandemic proportions (the “COVID-19 Pandemic”). The COVID-19 Pandemic poses a threat to the health and economic wellbeing of our employees, customers and vendors. Like most businesses world-wide, the COVID-19 Pandemic has impacted the Company financially; however, management cannot presently predict the scope and severity with which COVID-19 will impact our business, financial condition, results of operations and cash flows.

XML 20 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT POLICIES

3. SUMMARY OF SIGNIFICANT POLICIES

•

Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2021:

	Level 1		Level 2		Level 3		Total
Liabilities
Derivative Financial Instruments	$	—	$	—	$	40,471	$	40,471

	Amount
Balance December 31, 2020	$	—
Change in fair market value of derivative liabilities		40,471
Balance March 31, 2021	$	40,471

XML 21 R10.htm IDEA: XBRL DOCUMENT

INTANGIBLE AND OTHER ASSETS	3 Months Ended
INTANGIBLE AND OTHER ASSETS	Mar. 31, 2021
Notes to Financial Statements
INTANGIBLE AND OTHER ASSETS	4. INTANGIBLE AND OTHER ASSETS Patents and trademarks and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. As of March 31, 2021, intangible assets total $261,726, net of $115,846 of accumulated amortization. As of December 31, 2020, intangible assets total $261,726, net of $111,596 of accumulated amortization. Amortization expense for the three months ended March 31, 2021 and 2020 was $4,251 and $9,720, respectively. License and distributor rights were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of March 31, 2021.

XML 22 R11.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2021

RELATED PARTY TRANSACTIONS

5. RELATED PARTY TRANSACTIONS

During the three months ended March 31, 2021 and 2020, $0 and $22,000 was advanced by an officer and $7,616 and $0 was repaid, respectively .

Convertible Notes Related Party

Convertible Notes Payable Related Party consists of the following:	March 31, 2021			December 31, 2020
On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been accreted and charged to interest expenses as a financing expense in the amount of $105,880 during the year ended March 31, 2021 and 2020, respectively.	$	4,235,209		$	4,235,209
Unamortized debt discount		(2,295,307	)		(2,447,770)
Total, net of unamortized discount	$	1,939,302		$	1,787,439

XML 23 R12.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE	3 Months Ended
NOTES PAYABLE	Mar. 31, 2021
Notes to Financial Statements
NOTES PAYABLE	6. NOTES PAYABLE Secured debt offering During the period from May 22, 2013 and December 31, 2018, the Company entered into a 9% notes payable to nineteen investors and received proceeds of $552,000. The notes were due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.” As of March 31, 2021, $552,000 of the outstanding notes payable are past due and in default and have been classified as current notes payable.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

CONVERTIBLE NOTES PAYABLE

7. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable consists of the following:	March 31,			December 31,
	2021			2020
$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $7,358. The Company determined the derivative was immaterial as of December 31, 2020. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		40,000			40,000
Original issue discount		—			—
Unamortized debt discount		—			—
Total, net of unamortized discount		40,000			40,000

On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $24,834. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		135,000			135,000
Unamortized debt discount		—			—
Total, net of unamortized discount		135,000			135,000

On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $3,679. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		20,000			20,000
Unamortized debt discount		—			—
Total, net of unamortized discount		20,000			20,000

On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $2,759. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		15,000			15,000
Unamortized debt discount		—			—
Total, net of unamortized discount		15,000			15,000

On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $1,840. The Company determined the derivative was immaterial as of December 31, 2020 The note has reached maturity and is in default.		10,000			10,000
Unamortized debt discount		—			—
Total, net of unamortized discount		10,000			10,000

On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses in the amount of $12,534 and $12,674 for the three months ended March 31, 2021 and 2020, respectively.		352,075			352,075
Unamortized debt discount		(190,942	)		(203,476
Total, net of unamortized discount		161,133			148,599

Total Convertible Notes	$	381,133	$	368,599
Current portion:		220,000		220,000
Total long-term convertible notes	$	161,133	$	148,599

The Company determined the derivative liability of the options using the Binomial model. The variables used for the Binomial model as of March 31, 2021 are as listed below:

Risk free interest rate	0.16	%
Expected term (years)	.50
Expected volatility	110.66	%

XML 25 R14.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES License Agreement On October 17, 2019, Skinvisible entered an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to Skinvisible a license fee of $1,000,000 and a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to Skinvisible upon achieving regulatory approval milestones for certain drug products. The agreement is subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated on December 31, 2019. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement, as amended under the same terms to expire on September 30, 2020 and on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely. The milestones have not been reached as of March 31, 2021. The initial licensing fee has not been accrued due to the uncertainty of its collection. On February 3, 2020, we entered into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the agreement was further amended to provide additional assignment rights for its hand sanitizer products in exchange for $100,000.

XML 26 R15.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS

3 Months Ended

Mar. 31, 2021

Temporary Equity Disclosure [Abstract]

STOCK OPTIONS AND WARRANTS

9. STOCK OPTIONS AND WARRANTS

The following is a summary of option activity during the three months ended March 31, 2021.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2020		100,000		1. 51

Options granted and assumed		—		—
Options expired		—		—
Options canceled		—		—
Options exercised		—		—

Balance, March 31, 2021		100,000		1. 51

As of March 31, 2021, all stock options outstanding are exercisable.

Stock warrants -

The following is a summary of warrants activity during the year ended March 31, 2021.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2020		60,000	$	1.18

Warrants granted and assumed		—		—
Warrants expired		—		—
Warrants canceled		—		—
Warrants exercised		—		—

Balance, March 31, 2021		60,000	$	1.18

As of March 31, 2021, all stock warrants outstanding are exercisable.

XML 27 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Mar. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	11. SUBSEQUENT EVENTS In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to March 31, 2021 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Cash and cash equivalents

Accounting for derivatives

Fair Value of Financial Instruments

•

Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2021:

	Level 1		Level 2		Level 3		Total
Liabilities
Derivative Financial Instruments	$	—	$	—	$	40,471	$	40,471

	Amount
Balance December 31, 2020	$	—
Change in fair market value of derivative liabilities		40,471
Balance March 31, 2021	$	40,471

Revenue Recognition

Accounts Receivable

Stock-based Compensation

Earnings (loss) Per Share

Recently issued accounting Pronouncments

XML 29 R18.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTIES POLICIES (Tables)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Financial assets and liabilities measutred at fair value

	Level 1		Level 2		Level 3		Total
Liabilities
Derivative Financial Instruments	$	—	$	—	$	40,471	$	40,471

Changes in fair value of derivative liabilities

	Amount
Balance December 31, 2020	$	—
Change in fair market value of derivative liabilities		40,471
Balance March 31, 2021	$	40,471

XML 30 R19.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2021

Schedule of Convertible Notes Payable Related Party

Convertible Notes Payable Related Party consists of the following:	March 31, 2021			December 31, 2020
On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been accreted and charged to interest expenses as a financing expense in the amount of $105,880 during the year ended March 31, 2021 and 2020, respectively.	$	4,235,209		$	4,235,209
Unamortized debt discount		(2,295,307	)		(2,447,770)
Total, net of unamortized discount	$	1,939,302		$	1,787,439

XML 31 R20.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Schedule of Convertible Notes Payable

Convertible Notes Payable consists of the following:	March 31,			December 31,
	2021			2020
$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $7,358. The Company determined the derivative was immaterial as of December 31, 2020. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		40,000			40,000
Original issue discount		—			—
Unamortized debt discount		—			—
Total, net of unamortized discount		40,000			40,000

On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $24,834. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		135,000			135,000
Unamortized debt discount		—			—
Total, net of unamortized discount		135,000			135,000

On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $3,679. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		20,000			20,000
Unamortized debt discount		—			—
Total, net of unamortized discount		20,000			20,000

On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $2,759. The Company determined the derivative was immaterial as of December 31, 2020. The note has reached maturity and is in default.		15,000			15,000
Unamortized debt discount		—			—
Total, net of unamortized discount		15,000			15,000

On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company evaluated the conversion feature of the note and concluded that it represents an embedded derivative. As of March 31, 2021, the fair value of the derivative is $1,840. The Company determined the derivative was immaterial as of December 31, 2020 The note has reached maturity and is in default.		10,000			10,000
Unamortized debt discount		—			—
Total, net of unamortized discount		10,000			10,000

On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses in the amount of $12,534 and $12,674 for the three months ended March 31, 2021 and 2020, respectively.		352,075			352,075
Unamortized debt discount		(190,942	)		(203,476
Total, net of unamortized discount		161,133			148,599

Total Convertible Notes	$	381,133	$	368,599
Current portion:		220,000		220,000
Total long-term convertible notes	$	161,133	$	148,599

Variables used for valuation of deriviative instruments

Risk free interest rate	0.16	%
Expected term (years)	.50
Expected volatility	110.66	%

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Tables)

3 Months Ended

Mar. 31, 2021

Temporary Equity Disclosure [Abstract]

Summary of Options

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2020		100,000		1. 51

Options granted and assumed		—		—
Options expired		—		—
Options canceled		—		—
Options exercised		—		—

Balance, March 31, 2021		100,000		1. 51

Summary of Warrants

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2020		60,000	$	1.18

Warrants granted and assumed		—		—
Warrants expired		—		—
Warrants canceled		—		—
Warrants exercised		—		—

Balance, March 31, 2021		60,000	$	1.18

XML 33 R22.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative)	3 Months Ended
DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative)	Mar. 31, 2021
Date of Incorporation	Mar. 06, 1998

XML 34 R23.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		271 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021
Accounting Policies [Abstract]
Net loss	$ (435,505)	$ (430,084)	$ (35,135,913)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Assets and Liabilities at Fair Value (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Derivative financial instruments, balance	$ 40,471
Level 1
Derivative financial instruments, balance
Level 2
Derivative financial instruments, balance
Level 3
Derivative financial instruments, balance	$ 40,471

XML 36 R25.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Changes in Fair Value (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Derivative financial instruments, balance	$ 40,471
Change in fair market value of derivative liabilities	$ 40,471

XML 37 R26.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
	Mar. 31, 2021 $ / shares shares
Additional shares issuable	30,779,400
Stock price \| $ / shares	$ 0.11
Valuation model terms	As of March 31, 2021, the Company’s used the following assumptions to value the derivative liabilities using the for Binomial-Lattice valuation model. Stock price was $0.11, term 0.50 years, risk-free discount rate of 0.16% and volatility of 110.66%
Risk-free internest rate	16.00%
Expected term	6 months
Expected volatility	11066.00%
Options
Shares issuable	100,000
Warrants
Shares issuable	60,000
Convertible Notes
Shares issuable	30,619,400

XML 38 R27.htm IDEA: XBRL DOCUMENT

INTANGIBLE AND OTHER ASSETS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019
Notes to Financial Statements
Intangible Assets	$ 261,726		$ 261,726
Accumulated Amortization			$ 111,596
Amortization Expense	$ 4,251	$ 9,720

XML 39 R28.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Convertible notes payable	$ 161,133	$ 148,599
Total, net of Unamortized Discount	203,476	$ 54,450
Related Party Notes Payable
Convertible notes payable	4,235,209		$ 4,235,209
Unamortized debt discount	(2,295,307)		(2,447,770)
Total, net of Unamortized Discount	$ 1,939,302		$ 1,787,439

XML 40 R29.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS - Convertible Notes Payable Related Party (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2019
Convertible Notes Payable, Value			$ 2,464,480
Conversion terms			The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.
Accrued salaries			$ 617,915
Accrued vacation			64,423
Accrued Interest	$ 118,909	$ 134,955	966,203
Unpaid reimbursements			11,942
Cash advances			110,245
Beneficial conversion feature on convertible debt			$ 3,369,244
Convertible Notes Payable Related Party
Financing Expense	$ 105,590	$ 105,590

XML 41 R30.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Related Party Transactions [Abstract]
Due to Officers	$ 52,499		$ 52,499
Officer Advanced	0	$ 22,000
Repayment to officer	$ (7,116)

XML 42 R31.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)	67 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Dec. 31, 2018	Mar. 31, 2021	Dec. 31, 2020
Current notes payable		$ 552,000	$ 552,000
Nineteen Notes Payable
Notes payable, interest rate	9.00%
Notes payable, proceeds	$ 552,000
Notes payable, term	2 years

XML 43 R32.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Convertible note payable	$ 161,133	$ 148,599
Convertible Note 3
Convertible note payable		20,000
Unamortized debt discount
Total Net of Unamortized Discount		$ 20,000
Convertible Note 1
Convertible note payable	40,000		$ 40,000
Original issue discount
Unamortized debt discount
Total Net of Unamortized Discount	40,000		40,000
Convertible Note 2
Convertible note payable	135,000		135,000
Unamortized debt discount
Total Net of Unamortized Discount	135,000		135,000
Convertible Note 3
Convertible note payable	20,000
Unamortized debt discount
Total Net of Unamortized Discount	20,000
Convertible Note 4
Convertible note payable	15,000		15,000
Unamortized debt discount
Total Net of Unamortized Discount	15,000		15,000
Convertible Note 5
Convertible note payable	10,000		10,000
Unamortized debt discount
Total Net of Unamortized Discount	10,000		10,000
Convertible Note 6
Convertible note payable	352,075		352,075
Unamortized debt discount	(190,942)		(203,476)
Total Net of Unamortized Discount	161,133		148,599
Total Convertible Notes
Convertible note payable	381,133		368,599
Convertible notes payable current	220,000		220,000
Total Net of Unamortized Discount	$ 161,133		$ 148,599

XML 44 R33.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2019	Dec. 31, 2020	Jan. 27, 2017	Aug. 11, 2016	Feb. 17, 2016	Oct. 26, 2015
Convertible Notes Payable, Value			$ 2,464,480
Accrued salaries			617,915
Accrued vacation			64,423
Accrued Interest	$ 118,909	$ 134,955	966,203
Beneficial conversion feature on convertible debt			$ 3,369,244
Risk-free internest rate	16.00%
Expected term	6 months
Expected volatility	11066.00%
Convertible Note 2
Due date for unpaid interest	Oct. 26, 2017
Convertible Note 3
Convertible Notes Payable, Value							$ 20,000
Interest Rate							9.00%
Due date for unpaid interest	Feb. 17, 2018
Discount Of Current Share Price							90.00%
Convertible Note 4
Due date for unpaid interest	Aug. 11, 2018
Convertible Note 5
Due date for unpaid interest	Jan. 27, 2019
Convertible Note 6
Accrued Interest	$ 119,278
Beneficial conversion feature on convertible debt	280,076
Financing expense	50,974	$ 25,626
Convertible Note One
Convertible Notes Payable, Value	$ 40,000
Interest Rate	9.00%
Discount Of Current Share Price	90.00%
Convertible Note Two
Convertible Notes Payable, Value								$ 135,000
Interest Rate								9.00%
Discount Of Current Share Price								90.00%
Convertible Note Four
Convertible Notes Payable, Value						$ 15,000
Interest Rate						9.00%
Discount Of Current Share Price						90.00%
Convertible Note Five
Convertible Notes Payable, Value					$ 10,000
Interest Rate					9.00%
Discount Of Current Share Price					90.00%
Convertible Note Six
Interest Rate				10.00%
Outstanding notes value				$ 224,064
Accrued salaries				7,260
Accrued vacation				$ 1,473

XML 45 R34.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
	Jun. 10, 2020	Oct. 17, 2019	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
License fee		$ 1,000,000
Percent payment due to avoid termination of license agreement			50.00%
Proceeds from licensing fees received			$ 125,000
Payments for assignment rights	$ 100,000

XML 46 R35.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Summary of Options (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Stock Options And Warrants - Summary Of Options Details
Beginning Balance, number of shares	100,000	100,000
Beginning Balance, weighted average exercise price	$ 1.51	$ 1.51
Options granted and assumed, number of shares
Options granted and assumed, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Options cancelled, number of shares
Options cancelled, weighted average exercise price
Options exercised, number of shares
Options exercised, weighted average exercise price
Ending Balance, number of shares	100,000	100,000
Ending Balance, weighted average exercise price	$ 1.51	$ 1.51

XML 47 R36.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Temporary Equity Disclosure [Abstract]
Beginning balance, number of shares	60,000	60,000
Beginning balance, weighted average exercise price	$ 1.18
Warrants granted and assumed, number of shares
Warrants granted and assumed, weighted average exercise price
Warrants expired, number of shares
Warrants expired, weighted average exercise price
Warrants cancelled, number of shares
Warrants cancelled, weighted average exercise price
Warrants exercised, number of shares
Warrants exercised, weighted average exercise price
Ending balance, number of shares	60,000	60,000
Ending balance, weighted average exercise price	$ 1.18

XML 48 R37.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details Narrative) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Issued	4,539,843	4,539,843

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 74 245 1 false 30 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://skinvisible.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://skinvisible.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://skinvisible.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://skinvisible.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Stockholders' Deficit (Unaudited) Sheet http://skinvisible.com/role/StockholdersDeficit Condensed Consolidated Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://skinvisible.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY Sheet http://skinvisible.com/role/DescriptionOfBusinessAndHistory DESCRIPTION OF BUSINESS AND HISTORY Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PERESENTATION AND GOING CONCERN Sheet http://skinvisible.com/role/BasisOfPeresentationAndGoingConcern BASIS OF PERESENTATION AND GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://skinvisible.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - INTANGIBLE AND OTHER ASSETS Sheet http://skinvisible.com/role/IntangibleAndOtherAssets INTANGIBLE AND OTHER ASSETS Notes 10 false false R11.htm 00000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://skinvisible.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 00000012 - Disclosure - NOTES PAYABLE Notes http://skinvisible.com/role/NotesPayable NOTES PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://skinvisible.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://skinvisible.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://skinvisible.com/role/StockOptionsAndWarrants STOCK OPTIONS AND WARRANTS Notes 15 false false R16.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://skinvisible.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://skinvisible.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTIES POLICIES (Tables) Sheet http://skinvisible.com/role/SummaryOfSignificantAccountiesPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTIES POLICIES (Tables) Tables 18 false false R19.htm 00000020 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://skinvisible.com/role/RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://skinvisible.com/role/RelatedPartyTransactions 19 false false R20.htm 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) Notes http://skinvisible.com/role/ConvertibleNotesPayableTables CONVERTIBLE NOTES PAYABLE (Tables) Tables http://skinvisible.com/role/ConvertibleNotesPayable 20 false false R21.htm 00000022 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://skinvisible.com/role/StockOptionsAndWarrantsTables STOCK OPTIONS AND WARRANTS (Tables) Tables http://skinvisible.com/role/StockOptionsAndWarrants 21 false false R22.htm 00000023 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) Sheet http://skinvisible.com/role/DescriptionOfBusinessAndHistoryDetailsNarrative DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) Details http://skinvisible.com/role/DescriptionOfBusinessAndHistory 22 false false R23.htm 00000024 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) Sheet http://skinvisible.com/role/BasisOfPresentationAndGoingConcernDetailsNarrative BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) Details 23 false false R24.htm 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Assets and Liabilities at Fair Value (Details) Sheet http://skinvisible.com/role/SummaryOfSignificantAccountingPolicies-FinancialAssetsAndLiabilitiesAtFairValueDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Assets and Liabilities at Fair Value (Details) Details 24 false false R25.htm 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Changes in Fair Value (Details) Sheet http://skinvisible.com/role/SummaryOfSignificantAccountingPolicies-SummaryOfChangesInFairValueDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Changes in Fair Value (Details) Details 25 false false R26.htm 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://skinvisible.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://skinvisible.com/role/SummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 00000028 - Disclosure - INTANGIBLE AND OTHER ASSETS (Details Narrative) Sheet http://skinvisible.com/role/IntangibleAndOtherAssetsDetailsNarrative INTANGIBLE AND OTHER ASSETS (Details Narrative) Details http://skinvisible.com/role/IntangibleAndOtherAssets 27 false false R28.htm 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://skinvisible.com/role/RelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://skinvisible.com/role/RelatedPartyTransactionsTables 28 false false R29.htm 00000030 - Disclosure - RELATED PARTY TRANSACTIONS - Convertible Notes Payable Related Party (Details Narrative) Notes http://skinvisible.com/role/RelatedPartyTransactions-ConvertibleNotesPayableRelatedPartyDetailsNarrative RELATED PARTY TRANSACTIONS - Convertible Notes Payable Related Party (Details Narrative) Details 29 false false R30.htm 00000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://skinvisible.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://skinvisible.com/role/RelatedPartyTransactionsTables 30 false false R31.htm 00000032 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://skinvisible.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://skinvisible.com/role/NotesPayable 31 false false R32.htm 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) Notes http://skinvisible.com/role/ConvertibleNotesPayable-ScheduleOfConversionsOfStockDetails CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) Details 32 false false R33.htm 00000034 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://skinvisible.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://skinvisible.com/role/ConvertibleNotesPayableTables 33 false false R34.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://skinvisible.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://skinvisible.com/role/CommitmentsAndContingencies 34 false false R35.htm 00000036 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Options (Details) Sheet http://skinvisible.com/role/StockOptionsAndWarrants-SummaryOfOptionsDetails STOCK OPTIONS AND WARRANTS - Summary of Options (Details) Details 35 false false R36.htm 00000037 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details) Sheet http://skinvisible.com/role/StockOptionsAndWarrants-SummaryOfWarrantsDetails STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details) Details 36 false false R37.htm 00000038 - Disclosure - STOCKHOLDERS' DEFICIT (Details Narrative) Sheet http://skinvisible.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS' DEFICIT (Details Narrative) Details 37 false false All Reports Book All Reports skvi-20210331.xml skvi-20210331.xsd skvi-20210331_cal.xml skvi-20210331_def.xml skvi-20210331_lab.xml skvi-20210331_pre.xml http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true ZIP 55 0001663577-21-000297-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001663577-21-000297-xbrl.zip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end